Protein samples were subjected to
SDS-PAGE gels (Bio-Rad), electrophoresed, transferred to
Immobilon-P PVDF (Millipore) or
Immobilon-FL PVDF membranes (Millipore) and Western blotting (WB). The following primary antibodies were used:
PS1-NTF (a kind gift of Merck Research Laboratories);
PS1-CTF (MAB5232, Millipore);
PS2-CTF (1987–1, Epitomics); nicastrin was generated in our laboratory;
Aph-1aL (38–3600, Invitrogen); Pen-2 (
ab18189, Abcam); human IFITM3 (
anti-Fragilis,
ab109429, Abcam); mouse IFITM3 (
anti-Fragilis,
ab15592, Abcam); APP (22C11, MAB348, Millipore); SPP (317) was generated in our laboratory;
cleaved Notch1 (Val1744), Cell Signaling Technology and SM320, generated in our lab);
c-myc (9E10, Roche Life Science);
N-cadherin (D4R1H, #13116, Cell Signaling Technology);
Rab7 (B-3, sc-376362, Santa Cruz Biotechnology); EEA1 (Ab2900, Abcam);
β-actin (C4, sc-47778, Santa Cruz Biotechnology);
β-tubulin III (T8578, Sigma-Aldrich); tubulin (ab56676, Abcam). HRP-conjugated anti-rabbit and mouse secondary antibodies (NA9340V, NXA931V, GE Healthcare) for ECL substrate (Pierce) and
IRDye 800CW goat anti-rabbit IgG (H+L) or
anti-mouse IgG (H+L) secondary antibodies (925–32211, 925–32210, LI-COR) for
Odyssey CLx Imaging (LI-COR) were used. For quantification,
ImageJ and
Image Studio Lite (LI-COR) were used, respectively (for source gels see
Supplementary Figure 1).
Hur J.Y., Frost G.R., Wu X., Crump C., Pan S.J., Wong E., Barros M., Li T., Nie P., Zhai Y., Wang J.C., TCW J., Guo L., McKenzie A., Ming C., Zhou X., Wang M., Sagi Y., Renton A.E., Esposito B.T., Kim Y., Sadleir K.R., Trinh I., Rissman R.A., Vassar R., Zhang B., Johnson D.S., Masliah E., Greengard P., Goate A, & Li Y.M. (2020). Innate immunity protein IFITM3 modulates γ-secretase in Alzheimer disease. Nature, 586(7831), 735-740.